Source - SMW
Hutchison China MediTech Limited said it completed the enrollment of 527 patients in pivotal phase III faluca trial with fruquintinib in lung cancer.

Top-line Faluca data is expected to be reported in late 2018. If the data is positive, then the company said it would plan a second new drug application.

Fruquintinib (HMPL-013) is a highly selective small molecule drug candidate that has been shown to inhibit VEGFR 24 hours a day via an oral dose, with lower off-target toxicities compared to other targeted therapies

Faluca is a randomized, double-blind, placebo-controlled, multi-center, Phase III registration study of fruquintinib targeted at treating patients with advanced non-squamous NSCLC, who have failed two lines of systemic chemotherapy. 


At 9:41am: (LON:HCM) Hutchison China Meditech Ltd share price was +10p at 4440p